Blog

With many study subjects isolating themselves at home and many sites concerned about seeing subjects in-person for routine study visits, we are seeing an increased interest in remote visits. Sponsors that consider this for their studies often choose to complete the remote visits with video conferencing tools in order to allow more interaction between sites and subjects. Even for those with experience using video in clinical trials, using it in a home-based setting brings unique challenges.

Many rare diseases lack the well-characterized endpoints that we associate with outcome measures in more common diseases and disorders. Given that most clinical trials for rare diseases are small and often rely on assessments that are not designed specifically for the disease, it is important that every assessment is administered and scored correctly. In trials conducted in very small populations, missing, erroneous, or invalid data can have an outsized impact.

Centralized assessments are a method of testing clinical trial subjects that has significant potential advantages for rare and orphan disease trials. In a centralized assessment model, a small pool of trained and highly experienced raters conduct developmental and...

This blog series shares what’s happening day-to-day in our Innovation Lab long before we share the results in publications or at conferences. The VeraSci Innovation Lab was created to pair scientific knowledge with cutting-edge technology to improve the tools and...

  VeraSci developed the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) to assess proficiency in performing real-world tasks in a realistic environment. The VRFCAT, a digital tablet-based instrument, has been accepted into the FDA clinical outcome...

The Innovative Technologies Working Group of the International Society for CNS Clinical Trials and Methodology (ISCTM) held two special meetings to discuss challenges related to implementing remote assessments in CNS clinical trials in the context of COVID-19...

Many rare disease indications are studied predominantly, if not entirely, in pediatric populations. For many products, one or more of the key secondary endpoints will involve the use of developmental and cognitive assessments. These specific types of assessments are...

The COVID-19 pandemic and associated social distancing measures are creating unprecedented challenges for everyone working in clinical trials and drug development. In this series, we’re sharing some of the ways VeraSci is addressing these challenges. As we coordinate...

The VeraSci Innovation Lab was created to pair scientific knowledge with cutting-edge technology to improve the tools and measurements available for use in clinical trials. Each innovation is rigorously validated to ensure their usefulness in drug development...

Social distancing requirements based on COVID-19 have left many sponsors looking for alternatives to in-person study visits for both on-going clinical trials and clinical trials planning to start soon. As we’ve been having conversations with sponsors about their...